Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 254 clinical trials
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillance is to detect HCC at an early stage when it is still potentially curable. Currently only 4 out of 10 HCCs are detected …

ascites
liver ultrasound
fibroscan
platelet count
carcinoma
  • 0 views
  • 16 Feb, 2024
  • 10 locations
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.

fibrosis
fibroscan
vcte
fatty liver
hepatic fibrosis
  • 0 views
  • 05 Aug, 2020
Fatty Liver  

[1] Complications may include cirrhosis, liver cancer, and esophageal varices.

hepatitis c
cancer
  • 0 views
  • 14 Mar, 2022
  • 1 location
The Renal Deterioration Between Adjusted Dose TDF and Switching to TAF in CHB With Renal Impairment

Tenofovir is a nucleotide analog drug that works against both Human immunodeficiency virus (HIV) and HBV. TDF and TAF are prodrug of Tenofovir. TAF has a higher plasma stability than TDF, which makes TDF require a higher dose to get the concentration of drugs in the liver equal to the …

hepatitis c
renal function
renal impairment
tenofovir
HIV Infection
  • 0 views
  • 16 Feb, 2024
  • 1 location
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study) (PADSTONE)

Acute-on-chronic liver failure (ACLF) is life-threaten syndrome in patients with chronic liver disease. In China, hepatitis B virus (HBV) is the main etiology of cirrhosis and HBV-ACLF is characterized by multiple organs failure (liver, coagulation and kidney, etc.) and associated with high risk of short-tern death.

  • 0 views
  • 23 Nov, 2021
  • 1 location
Prospective Cohort Study of Disease and Outcomes in Cirrhosis

A population based incidence cohort will enroll patients newly diagnosed with cirrhosis to investigate disease characteristics and outcomes, explore mechanisms predicting early death and hospital admission, and assess new monitoring tools in treatment and prevention of cirrhosis.

imaging techniques
cirrhosis
  • 0 views
  • 16 Feb, 2024
  • 1 location
The European NAFLD Registry

The ultimate goals are to better understand the drivers of interpatient variation in disease pathophysiology and severity and to utilise this information to develop and validate biomarkers that, singly or in combination, enable detection and monitoring of disease progression and/or from NAFL through NASH to fibrosis and cirrhosis.

diabetes
cirrhosis
metabolic syndrome
nonalcoholic steatohepatitis
hypertension
  • 0 views
  • 16 Feb, 2024
  • 37 locations
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies

The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for comparative purpose a cohort of subjects with diabetes and/or obesity and/or other risk factors (i.e. psoriasis, …

diabetes
hepatitis c
cirrhosis
metabolic syndrome
inflammatory bowel disease
  • 0 views
  • 16 Feb, 2024
  • 1 location
Characterization of Methylation Patterns in Hepatocellular Carcinoma

This study is being performed as part of the development process of the Liver EpiCheck test which includes the identification of different methylation profiles in HCC (hepatocellular carcinoma) patients compare to cancer free control in blood samples

ascites
carcinoma
nash
cirrhosis
fatty liver
  • 0 views
  • 16 Feb, 2024
  • 5 locations
Non-invasive Evaluation Program for TIPS and Follow Up Network 2 (NEPTUN2)

Evaluation of non-invasive prognostic parameters in patients receiving transjugular intrahepatic portosystemic shunt (TIPS) for complications of portal hypertension. Patients are cared according to the local standardized follow up program. Clinical and laboratory data from standard patient care are evaluated for potential prognostic value.

hypertension
portosystemic shunt
  • 0 views
  • 05 Aug, 2020